Joseph J. Palamar

Joseph J. Palamar

Auto-generated profile, based on publicly available information

Joseph J. Palamar

Department of Population Health, NYU Grossman School of Medicine, NYU Langone Health, New York

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2017 in Drug and Alcohol Dependence
Verified
Journal Article
Closed access
BHBenjamin H. Han
Benjamin H. Han
AMAlison A. Moore
Alison A. Moore
SSScott Sherman
Scott Sherman
KKKatherine M. Keyes
Katherine M. Keyes
JPJoseph J. Palamar
Joseph J. Palamar

1 April 2020 in JAMA Internal Medicine
Verified
Journal Article
Open access
PDF file
BHBenjamin H. Han
Benjamin H. Han
JPJoseph J. Palamar
Joseph J. Palamar
With the legalization of cannabis in many states for medical and/or recreational purposes, there is increasing interest in using cannabis to treat a variety of long-term health conditions and symptoms common among older adults. The use of cannabis in the past year by adults 65 years and older in the United States increased sharply from 0.4% in 2006 and 2007 to 2.9% in 2015 and 2016.1,2 This study examines the most recent national trends in cannabis use to determine whether cannabis use has continued to increase among older adults and to further examine trends in use among subgroups of older adults.

21 October 2016 in Addiction
Verified
Journal Article
Closed access
PDF file
BHBenjamin H. Han
Benjamin H. Han
SSScott Sherman
Scott Sherman
PMPia M. Mauro
Pia M. Mauro
SMSilvia S. Martins
Silvia S. Martins
JRJames Rotenberg
James Rotenberg
JPJoseph J. Palamar
Joseph J. Palamar


Verified
Journal Article
Open access
PDF file
MFMei Fu
Mei Fu
DADeborah Axelrod
Deborah Axelrod
AGAmber A. Guth
Amber A. Guth
CCCharles M. Cleland
Charles M. Cleland
CRCaitlin E. Ryan
Caitlin E. Ryan
GMGail D'Eramo Melkus
Gail D'Eramo Melkus
Many breast cancer survivors have coexistent chronic diseases or comorbidities at the time of their cancer diagnosis. The purpose of the study was to evaluate the association of comorbidities on breast cancer survivors’ quality of life. A prospective design was used to recruit 140 women before cancer surgery, 134 women completed the study. Comorbidities were assessed using self-report and verified by medical record review and the Charlson Comorbidity Index (CCI) before and 12-month after cancer surgery. Quality of life was evaluated using Short-Form Health Survey (SF-36 v2). Descriptive statistics, chi-square tests, t-tests, Fisher’s exact test, and correlations were performed for data analysis. A total of 28 comorbidities were identified. Among the 134 patients, 73.8% had at least one of the comorbidities, 54.7% had 2–4, and only 7.4% had 5–8. Comorbidities did not change at 12 months after surgery. Numbers of comorbidities by patients’ self-report and weighted categorization of comorbidities by CCI had a similar negative correlation with overall quality of life scores as well as domains of general health, physical functioning, bodily pain, and vitality. Comorbidities, specifically hypertension, arthritis, and diabetes, were associated with poorer quality of life in multiple domains among breast cancer survivors. Future research should consider the combined influence of comorbidity and cancer on patients’ quality of life.

31 March 2022 in Drug and Alcohol Dependence
Verified
Journal Article
Closed access
JPJoseph J. Palamar
Joseph J. Palamar
DCDaniel Ciccarone
Daniel Ciccarone
CRCaroline Rutherford
Caroline Rutherford
KKKatherine M. Keyes
Katherine M. Keyes
TCThomas H. Carr
Thomas H. Carr
LCLinda B. Cottler
Linda B. Cottler